Perrigo Company plc (NYSE:PRGO) Receives Consensus Recommendation of “Reduce” from Analysts

Perrigo Company plc (NYSE:PRGO) has received an average rating of “Reduce” from the six research firms that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $20.3333.

Several brokerages recently issued reports on PRGO. Jefferies Financial Group cut their target price on shares of Perrigo from $27.00 to $23.00 and set a “hold” rating for the company in a research report on Monday, October 27th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Perrigo in a research note on Monday, December 22nd. Wall Street Zen cut Perrigo from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Zacks Research cut Perrigo from a “hold” rating to a “strong sell” rating in a report on Friday, November 7th. Finally, Canaccord Genuity Group decreased their price target on shares of Perrigo from $40.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, November 6th.

Insider Activity

In related news, Director Geoffrey M. Parker acquired 7,500 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The shares were purchased at an average price of $14.18 per share, for a total transaction of $106,350.00. Following the completion of the acquisition, the director owned 17,375 shares in the company, valued at approximately $246,377.50. This represents a 75.95% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Geneos Wealth Management Inc. grew its holdings in Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after acquiring an additional 786 shares during the last quarter. Huntington National Bank raised its position in Perrigo by 237.8% during the 2nd quarter. Huntington National Bank now owns 1,054 shares of the company’s stock valued at $28,000 after purchasing an additional 742 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in Perrigo by 54.6% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,201 shares of the company’s stock worth $32,000 after buying an additional 424 shares during the period. Hantz Financial Services Inc. grew its position in shares of Perrigo by 101.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,234 shares of the company’s stock worth $33,000 after buying an additional 620 shares during the last quarter. Finally, Kestra Investment Management LLC increased its stake in shares of Perrigo by 57.1% during the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after buying an additional 642 shares during the period. Institutional investors own 95.91% of the company’s stock.

Perrigo Stock Up 2.6%

PRGO stock opened at $15.08 on Friday. The company’s 50 day moving average is $13.96 and its 200 day moving average is $20.40. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of -39.67 and a beta of 0.40. The company has a current ratio of 2.51, a quick ratio of 1.44 and a debt-to-equity ratio of 0.81. Perrigo has a 1-year low of $12.17 and a 1-year high of $30.93.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.05. The business had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Perrigo had a negative net margin of 1.21% and a positive return on equity of 9.16%. The business’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.81 EPS. Perrigo has set its FY 2025 guidance at 2.700-2.80 EPS. Sell-side analysts predict that Perrigo will post 2.56 EPS for the current fiscal year.

Perrigo Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 16th. Shareholders of record on Friday, November 28th were given a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a yield of 7.7%. The ex-dividend date was Friday, November 28th. Perrigo’s dividend payout ratio is presently -305.26%.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.